Evaluating Rebound Hypotension Following Vasopressor Discontinuation Strategies in Patients With Septic Shock.

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Skyler Starkel, Brian R Schuler, Mary P Kovacevic, Jeremy R DeGrado, Paul M Szumita, Kevin M Dube
{"title":"Evaluating Rebound Hypotension Following Vasopressor Discontinuation Strategies in Patients With Septic Shock.","authors":"Skyler Starkel, Brian R Schuler, Mary P Kovacevic, Jeremy R DeGrado, Paul M Szumita, Kevin M Dube","doi":"10.1177/10600280251335344","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 2021 Surviving Sepsis guidelines recommend which vasopressor to initiate first; however, there is a paucity of data to guide the order of vasopressor discontinuation. Retrospective studies have demonstrated an increased risk of hypotension within 24 hours if vasopressin is discontinued first; however, using a shorter timeframe may be of higher clinical relevance and more reflective of vasopressor pharmacokinetic properties.</p><p><strong>Objective: </strong>The purpose of this study was to evaluate differences in the incidence of rebound hypotension within the first 6 hours following norepinephrine or vasopressin discontinuation in patients with septic shock.</p><p><strong>Methods: </strong>This was a single-center, retrospective analysis of adult patients with septic shock admitted to an intensive care unit (ICU) who had either vasopressin (AVP1) or norepinephrine (NE1) discontinued first between January 1, 2021 and December 31, 2021. The major outcome was the incidence of hypotension within 6 hours of first discontinued agent. A Kaplan-Meier curve evaluated time to hypotension. Notable minor outcomes included incidence of hypotension within 12 and 24 hours, ICU length of stay (LOS), ICU mortality, and time to shock resolution.</p><p><strong>Results: </strong>During the study period, 580 patients were evaluated for inclusion, of which 209 were included: 150 in the NE1 group and 59 in the AVP1 group. There was no difference in incidence of hypotension within 6 (54% vs 61%), 6-12 (14.7% vs 10.2%), or 12-24 (6.7% vs 10.2%) hours, ICU LOS, ICU mortality, and shock resolution between groups. The Kaplan-Meier curve showed no differences between groups in time to hypotension within 6 hours of vasopressor discontinuation (<i>p</i> = 0.1)Conclusion and Relevance:This is the first study to evaluate the impact of vasopressor discontinuation order in septic shock within 6 hours, finding no differences in hypotension regardless of discontinuation order. Application of this data gives reassurance the order of vasopressor discontinuation may not impact clinical outcomes.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280251335344"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280251335344","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The 2021 Surviving Sepsis guidelines recommend which vasopressor to initiate first; however, there is a paucity of data to guide the order of vasopressor discontinuation. Retrospective studies have demonstrated an increased risk of hypotension within 24 hours if vasopressin is discontinued first; however, using a shorter timeframe may be of higher clinical relevance and more reflective of vasopressor pharmacokinetic properties.

Objective: The purpose of this study was to evaluate differences in the incidence of rebound hypotension within the first 6 hours following norepinephrine or vasopressin discontinuation in patients with septic shock.

Methods: This was a single-center, retrospective analysis of adult patients with septic shock admitted to an intensive care unit (ICU) who had either vasopressin (AVP1) or norepinephrine (NE1) discontinued first between January 1, 2021 and December 31, 2021. The major outcome was the incidence of hypotension within 6 hours of first discontinued agent. A Kaplan-Meier curve evaluated time to hypotension. Notable minor outcomes included incidence of hypotension within 12 and 24 hours, ICU length of stay (LOS), ICU mortality, and time to shock resolution.

Results: During the study period, 580 patients were evaluated for inclusion, of which 209 were included: 150 in the NE1 group and 59 in the AVP1 group. There was no difference in incidence of hypotension within 6 (54% vs 61%), 6-12 (14.7% vs 10.2%), or 12-24 (6.7% vs 10.2%) hours, ICU LOS, ICU mortality, and shock resolution between groups. The Kaplan-Meier curve showed no differences between groups in time to hypotension within 6 hours of vasopressor discontinuation (p = 0.1)Conclusion and Relevance:This is the first study to evaluate the impact of vasopressor discontinuation order in septic shock within 6 hours, finding no differences in hypotension regardless of discontinuation order. Application of this data gives reassurance the order of vasopressor discontinuation may not impact clinical outcomes.

评估感染性休克患者停用血管加压药物后的反跳性低血压。
背景:2021年生存脓毒症指南推荐首先使用哪种血管加压药;然而,缺乏数据来指导血管加压药的停药顺序。回顾性研究表明,如果先停用抗利尿激素,24小时内发生低血压的风险会增加;然而,使用较短的时间框架可能具有更高的临床相关性,更能反映血管加压药代动力学特性。目的:本研究的目的是评估脓毒性休克患者停用去甲肾上腺素或加压素后6小时内反跳性低血压发生率的差异。方法:这是一项单中心回顾性分析,研究对象是在2021年1月1日至2021年12月31日期间首先停用抗利尿激素(AVP1)或去甲肾上腺素(NE1)的重症监护病房(ICU)住院的感染性休克成年患者。主要结局是首次停药后6小时内低血压的发生率。Kaplan-Meier曲线评估低血压发生的时间。值得注意的次要结果包括12和24小时内低血压的发生率、ICU住院时间(LOS)、ICU死亡率和休克消退时间。结果:在研究期间,580例患者被评估纳入,其中209例纳入:NE1组150例,AVP1组59例。在6小时(54%对61%)、6-12小时(14.7%对10.2%)或12-24小时(6.7%对10.2%)内的低血压发生率、ICU LOS、ICU死亡率和休克缓解方面,组间无差异。Kaplan-Meier曲线显示,两组患者停药6小时内出现低血压的时间无差异(p = 0.1)。结论及相关性:本研究首次评估了感染性休克6小时内停药顺序对降压效果的影响,无论停药顺序如何,降压效果均无差异。这些数据的应用保证了血管加压药停药的顺序不会影响临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
166
审稿时长
3-8 weeks
期刊介绍: Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信